초록 ▼

A micro-machined drug delivery device and method of use for the delivery of labile drugs is disclosed. A micro-machined sensing device and method of use is also disclosed. A micro-machined drug delivery and sensing device and method of use is additionally disclosed. All three devices are intended to

A micro-machined drug delivery device and method of use for the delivery of labile drugs is disclosed. A micro-machined sensing device and method of use is also disclosed. A micro-machined drug delivery and sensing device and method of use is additionally disclosed. All three devices are intended to be inserted into a patient's body. The drug delivery devices allow for the mixing of drug components prior to the release of the mixture into the patient's body where the mixture is labile. The micro-machined sensing device is suitable for monitoring the concentration of a specific chemical in a patient's body fluids when the monitoring requires a labile reagent that must be mixed prior to introduction of the body fluid into the sensing device. The micro-machined drug delivery and sensing device is especially applicable in situations where the prompt delivery of labile drugs is necessary.

대표청구항 ▼

A micro-machined drug delivery device and method of use for the delivery of labile drugs is disclosed. A micro-machined sensing device and method of use is also disclosed. A micro-machined drug delivery and sensing device and method of use is additionally disclosed. All three devices are intended to

A micro-machined drug delivery device and method of use for the delivery of labile drugs is disclosed. A micro-machined sensing device and method of use is also disclosed. A micro-machined drug delivery and sensing device and method of use is additionally disclosed. All three devices are intended to be inserted into a patient's body. The drug delivery devices allow for the mixing of drug components prior to the release of the mixture into the patient's body where the mixture is labile. The micro-machined sensing device is suitable for monitoring the concentration of a specific chemical in a patient's body fluids when the monitoring requires a labile reagent that must be mixed prior to introduction of the body fluid into the sensing device. The micro-machined drug delivery and sensing device is especially applicable in situations where the prompt delivery of labile drugs is necessary. the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. American College of Cardiology, 2000. 35(1): p. 176-182. Ensor, C.M., et al., Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J. Biol. Chem., 1990. 265(25): p. 14888-91. Ensor, C.M. and H.H. Tai, Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. Biochim. Biophys. Acta, 1994. 1208(1): p. 151-6. Ensor, C.M., H. Zhang, and H.H. Tai, Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J., 1998. 330(Pt 1): p. 103-8. Drug delivery showing strength in wake of drug efficacy efforts. Chemical Market Reporter, 1997. 252 (Sep. ): p. 10. Drug delivery system: polymers expected to dominate world market by 1996. Gazeta Mercantil. Wilson, G. and Y. Hu, Enzyme-based biosensors for in vivo measurements. Chem. Rev., 2000. 100(7): p. 2693-2704. Madou, M.J. and M. Tierney. 1994: Micro-electrochemical valves and methods, United States Patent, 5,368,704. Glaxo Wellcome, I., www.glaxowellcome.com. Wilson, G. and Y. Hu, Enzyme-based biosensors for in vivo measurements. Chem. Rev., 2000. 100(7): p. 2693-2704. Bowyer, J.R., et al., Energy Res. Abstr., 1991: p. 30. Xie, S.L., E. Wilkins, and P. Atanasov, Sens. Actuators, 1994. 17(2): p. 133-42. Madou, M.J. and M. Tierney. 1994: Micro-electrochemical valves and methods, United States Patent, 5,368,704. Glaxo Wellcome, I., www.glaxowellcome.com. United Therapeutics Corporation S-1 filing. Securities and Exchange Commission: EDGAR, 1999 (Apr.). Badesch, D.E.A., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann. Intern. Med., 2000. 132(6): p.425-434. Dollery, C.T., Ther. Drugs. 1998. Hooper, M.M., M.D., et al., A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. American College of Cardiology, 2000. 35(1): p. 176-182. Ensor, C.M., et al., Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. J. Biol. Chem., 1990. 265(25): p. 14888-91. Ensor, C.M. and H.H. Tai, Bacterial expression and site-directed mutagenesis of two critical residues (tyrosine-151 and lysine-155) of human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase. Biochim. Biophys. Acta, 1994. 1208(1): p. 151-6. Ensor, C.M., H. Zhang, and H.H. Tai, Purification, cDNA cloning and expression of 15-oxoprostaglandin 13-reductase from pig lung. Biochem. J., 1998. 330(Pt 1): p. 103-8. Drug delivery showing strength in wake of drug efficacy efforts. Chemical Market Reporter, 1997. 252 (Sep. ): p. 10. Drug delivery deveopment proliferation. Medical & Healthcare Marketplace Guide, 1997 (Jan.). Drug delivery market faces increased consolidation. Chemical Market Reporter, 1998 (Nov.). Drug delivery systems: polymers expected dominate world market by 1996. Gazeta Mercantil. Drug delivery changing times. Med. Ad. News, 1999. 18 (Aug.): p. 8. O97/024097, WO; WO97/034557, WO; WO97/036561, WO; WO97/036562, WO; WO97/045259, WO; WO97/045259, WO; WO98/024621, WO; WO98/027920, WO; WO98/029480, WO; WO99/014047, WO; WO99/016400, WO; WO99/022619, WO; WO99/025283, WO; WO99/032288, WO; WO99/055265, WO; 00/10497, WO